LUX-Lung 7

一行要約

未治療 EGFR 変異陽性 (ex19del / L858R) NSCLC 1L における 2nd-gen Afatinib vs 1st-gen Gefitinib の phase IIb head-to-head 比較。PFS HR 0.73 (11.0 vs 10.9 mo) で中央値差はわずかだが TTF (time to treatment failure) HR 0.73 と PFS2 HR 0.73 で一貫した benefit を示し、EGFR-TKI 世代間比較を初めて前向きに検証した試験。

試験デザイン

• 対象: Stage IIIB/IV NSCLC、EGFR ex19del or L858R、未治療、ECOG PS 0-1、N=319 (1:1)
• 介入群 (n=160) : Afatinib 40 mg/day
• 対照群 (n=159) : Gefitinib 250 mg/day
• 層別化: 変異タイプ (ex19del vs L858R)、脳転移有無
• 主要評価項目: Co-primary — PFS、TTF、OS (いずれも hierarchical に検定)
• デザイン上の留意: Phase IIb であり OS に対する統計的検出力は十分でない

主要結果

• PFS (co-primary) : HR 0.73 (95% CI 0.57–0.95, p=0.017)、median 11.0 vs 10.9 mo — HR で有意だが中央値差はわずか
• TTF (co-primary) : HR 0.73 (95% CI 0.58–0.92, p=0.007)、median 13.7 vs 11.5 mo
• OS (co-primary) : HR 0.86 (95% CI 0.66–1.12, p=0.258)、median 27.9 vs 24.5 mo — 有意差なし
• ORR: 70% vs 56% (p=0.008) — Afatinib 群で有意に高い
• PFS2: HR 0.73 (p=0.029)、Afatinib 先行の sequential 戦略の benefit を示唆
• Grade ≥3 AE: Afatinib 31% vs Gefitinib 18%。Afatinib で下痢 (13% vs 1%)・皮疹 (9% vs 3%) が多い

臨床的意義

• 世代間 head-to-head の先駆: 1st vs 2nd-gen EGFR-TKI を初めて直接比較。PFS HR は有意だが中央値差はわずかで、臨床的意義の解釈は divided
• Sequential strategy: PFS2 の benefit は「Afatinib→T790M 出現→Osimertinib」sequential 戦略 (GioTag study で後追い検証) の理論的根拠
• 毒性 trade-off: Afatinib は ORR・PFS で優るが Grade ≥3 AE が多く、用量調整の必要性が高い。患者選択 (若年・PS 良好 vs 高齢・合併症多い) に影響
• FLAURA による世代交代: FLAURA (Osimertinib vs 1st-gen) が PFS HR 0.46 を示し、2nd-gen の臨床的 niche は狭まった

Open Questions

• 2nd-gen の残存 niche: Uncommon mutations (G719X / L861Q / S768I) での Afatinib 優位性は本試験では検討されていない
• GioTag sequential の prospective 検証: Afatinib → Osimertinib sequential が FLAURA single-agent Osimertinib を上回るかの前向きデータは不在
• 4th-gen TKI 時代の sequential 最適化: C797S 後の 4th-gen 開発が進む中、世代間 sequential の全体像はさらに複雑化

重要論文 Top 10

1. ★★★★★ Park et al. LancetOncol 2016 — Primary publication — PFS HR 0.73、初の世代間 head-to-head
2. Paz-Ares et al. AnnOncol 2017 (OS final) — OS update — HR 0.86 (有意差なし)
3. ★★★★★ Sequist et al. JClinOncol 2013 (LUX-Lung-3) — Afatinib vs chemo — 2nd-gen 1L 確立
4. Hochmair et al. (GioTag) — Real-world Afatinib→Osimertinib sequential
5. Soria et al. (FLAURA) — 3rd-gen Osimertinib — 世代間競争の決着

関連エンティティ・概念

• 薬剤: Afatinib / Gefitinib
• 関連試験: LUX-Lung-3 (Afatinib vs chemo) / FLAURA (Osimertinib vs 1st-gen) / NEJ002 (Gefitinib vs chemo) / IPASS (Gefitinib vs chemo、初の EGFR selection)
• 関連遺伝子: EGFR (ex19del, L858R, T790M)
• 関連概念: T790M-mediated-resistance
• ドメイン: lung-cancer-treatment

関連論文

Clinical-NSCLC-Driver negative

• Takano et al. LungCancer 2019 — Improvement in the survival of patients with stage IV non-small-cell lung cancer experience in a single institutional

Clinical-NSCLC-EGFR

• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Westover et al. AnnOncol 2018 — Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
• Lim et al. CancerTreatRev 2018 — Acquired resistance to EGFR targeted therapy in non-small cell lung cancer mechanisms and therapeutic strategies
• Wu et al. LancetOncol 2014 — Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung
• Yang et al. LancetOncol 2015 — Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations a
• Park et al. LancetOncol 2016 — Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer
• Wu et al. LancetOncol 2017 — Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung
• Schuler et al. LungCancer 2019 — First-line afatinib for advanced EGFRm+ NSCLC analysis of long-term responders in the LUX-lung 3, 6, and 7 trials
• Kobayashi et al. MolCancerTher 2017 — Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung